Compare BridgeBio Pharma Inc (BBIO) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Utilities Select Sector SPDR Fund — how do they compare? BridgeBio Pharma Inc trades at $82.33 (market cap $16.46B), while Utilities Select Sector SPDR Fund trades at $45.29. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| BBIO | XLU | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | — |
52-Week High | $90.17 | $47.73 |
52-Week Low | $44.81 | $40.99 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
XLU trades at $45.72, up 0.68% today, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The ETF benefits from growing electricity demand driven by AI data centers and clean energy transitions, positioning utilities as both defensive and growth-oriented investments. Recent news highlights XLU's role in powering AI infrastructure, with top holdings securing long-term power agreements with major tech firms.
Outlook remains positive due to structural power demand growth, though risks include regulatory changes and grid capacity constraints. Wall Street sentiment is bullish with strong institutional interest, but investors should monitor interest rate sensitivity and execution of capital expenditure plans for new power generation assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
